Date: 2014-11-05
Type of information: Capital increase
Company: MDXHealth (Belgium)
Investors:
Amount: € 12.33 million ($ 15.43 million)
Funding type: capital increase
Planned used: The net proceeds of the private placement will be used to support and scale-up MDxHealth\'s U.S.-based managed care and related healthcare reimbursement efforts, together with its sales and marketing efforts. In addition, depending on the amount raised, the net proceeds would be used to accelerate product development and for general corporate purposes.
Others: * On November 7, 2014, MDxHealth, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced, in conformity with article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that further to the capital increase that was completed on Friday, November 7, 2014, its share capital has increased from € 27,321,762.02 to € 30,053,884.52 and the number of issued and outstanding shares have increased from 34,251,303 to 37,676,303, through the issuance of 3,425,000 new shares. * On November 5, 2014, MDxHealth announced that it has successfully raised € 12,330,000.00 (US$ 15,429,762.00) in gross proceeds by means of a private placement of 3,425,000 new shares with a group of institutional, qualified and professional investors in and outside Belgium at an issue price of € 3.60 (or US$ 4.51) per share. The closing price of the MDxHealth share on Euronext Brussels on November 4, 2014, before the launch of the private placement was € 3.599 per share. The placement was more than twice oversubscribed by a broad and international range of institutional investors. Petercam NV/SA acted as Sole Lead Manager and Book Runner in the private placement. The payment and delivery of the new shares is expected to take place on November 7, 2014, at which date the new shares are also expected to be admitted to listing. The new shares to be issued will have the same rights and benefits as, and rank pari passu in all respects with, the existing and outstanding shares of MDxHealth at the moment of their issuance and will be entitled to distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares. As a result of the issuance of new shares, the company\'s share capital will increase from € 27,321,762.02 to € 30,053,884.52 and its issued and outstanding shares will increase by 10 % from 34,251,303 to 37,676,303 ordinary shares. * On November 4, 2014, MDxHealth announced that it has launched an offering of up to 3,425,000 new shares by means of a private placement with a group of institutional, qualified and professional investors in and outside Belgium. Petercam NV/SA acts as Sole Lead Manager and Book Runner for the private placement, which shall be structured as an accelerated bookbuilding. The bookbuilding procedure will commence immediately and is expected to close on November 5, 2014, subject to acceleration or extension of the timetable. MDxHealth will request the admission to trading of the newly issued shares on Euronext Brussels. The trading in MDxHealth shares on Euronext Brussels will be suspended throughout the bookbuilding period. Trading in the stock is expected to resume following the publication of the results of the placement.
Therapeutic area: Cancer - Oncology - Diagnostic - Technology - Services
